BDX
Becton, Dickinson and Company
Price Chart
Latest Quote
$141.61
-3.55 (-2.45%)
Current Price
| Previous Close | $145.16 |
| Open | $144.50 |
| Day High | $145.47 |
| Day Low | $140.65 |
| Volume | 2,049,233 |
Stock Information
| Quarterly Dividend / Yield | $4.20 / 2.89% |
| Shares Outstanding | 275.54M |
| Quarterly Dividend Yield | 2.89% |
| Quarterly Dividend | $4.20 |
| Total Debt | $17.28B |
| Cash Equivalents | $816.00M |
| Revenue | $22.23B |
| Net Income | $1.65B |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $39.02B |
| P/E Ratio | 24.71 |
| EPS (TTM) | $5.73 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $56.46B |
| Sales | $22.23B |
| Income | $1.65B |
| Book/sh | $87.58 |
| Cash/sh | $2.96 |
| Employees | 60K |
Financial Ratios
| Quick Ratio | 0.35 |
| Current Ratio | 0.94 |
| Debt/Eq | 71.60 |
Returns & Margins
| ROA | 4.38% |
| ROE | 6.67% |
| Gross Margin | 47.09% |
| Operating Margin | 14.74% |
| Profit Margin | 5.12% |
Ownership
| Insider Ownership | 0.41% |
| Institutional Ownership | 99.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.58 |
| PEG | 1.11 |
| P/S | 1.76 |
| P/B | 1.62 |
Analyst Data
| Recommendation | buy |
| Target Price | $180.69 |
Technical Indicators
| SMA20 | $146.49 |
| SMA50 | $148.33 |
| SMA200 | $152.13 |
| RSI | 38.63 |
| ATR | 3.3944 |
| Shares Float | 274.74M |
| Short Float | 2.98% |
| Short Ratio | 2.14 |
| Volatility | 0.28 |
| Rel Volume | 1.28 |
Performance History
| Week | -4.18% |
| Month | +0.18% |
| Quarter | -9.79% |
| 6 Months | -8.76% |
| YTD | -6.35% |
| Year | +7.23% |
| 3 Years | -23.78% |
| 5 Years | -17.92% |
| 10 Years | +28.37% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $141.61 | 2,920,800 |
| 2026-06-16 | $145.16 | 1,509,900 |
| 2026-06-15 | $145.52 | 1,760,200 |
| 2026-06-12 | $146.24 | 1,966,900 |
| 2026-06-11 | $147.35 | 1,639,900 |
| 2026-06-10 | $147.79 | 1,748,000 |
| 2026-06-09 | $152.04 | 2,214,900 |
| 2026-06-08 | $148.94 | 1,926,000 |
| 2026-06-05 | $150.10 | 2,077,400 |
| 2026-06-04 | $148.51 | 2,241,600 |
| 2026-06-03 | $144.59 | 1,609,700 |
| 2026-06-02 | $143.42 | 2,693,500 |
| 2026-06-01 | $144.31 | 2,387,000 |
| 2026-05-29 | $146.09 | 3,728,400 |
| 2026-05-28 | $147.37 | 3,214,500 |
| 2026-05-27 | $146.21 | 2,878,200 |
| 2026-05-26 | $146.72 | 3,243,500 |
| 2026-05-22 | $146.60 | 1,291,300 |
| 2026-05-21 | $145.23 | 1,986,200 |
| 2026-05-20 | $145.92 | 2,479,100 |
| 2026-05-19 | $145.92 | 4,219,500 |
| 2026-05-18 | $141.35 | 3,814,100 |
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
đ° Latest News
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Zacks âĸ 2026-06-16T13:54:00Z
BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist
Insider Monkey âĸ 2026-06-15T19:24:06Z
Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-12T18:17:19Z
Is ResMed Stock Underperforming the Dow?
Barchart âĸ 2026-06-11T13:20:26Z
Jim Cramer on Becton, Dickinson: âI Think You Buy Some and Then You Waitâ
Insider Monkey âĸ 2026-06-06T15:06:15Z
Is It Smart To Buy Becton, Dickinson and Company (NYSE:BDX) Before It Goes Ex-Dividend?
Simply Wall St. âĸ 2026-06-05T10:11:42Z
Becton, Dickinson and Company Stock: Is BDX Underperforming the Healthcare Sector?
Barchart âĸ 2026-06-04T03:15:30Z
Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?
Simply Wall St. âĸ 2026-06-01T14:07:27Z
Is Stryker Stock Underperforming the S&P 500?
Barchart âĸ 2026-06-01T10:59:22Z
Intuitive Surgical Stock: Is ISRG Underperforming the Healthcare Sector?
Barchart âĸ 2026-05-31T15:56:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $11,915,000,000 | $11,053,000,000 | $11,202,000,000 | $10,393,000,000 |
| Cost Of Revenue | $11,915,000,000 | $11,053,000,000 | $11,202,000,000 | $10,393,000,000 |
| Total Revenue | $21,840,000,000 | $20,178,000,000 | $19,372,000,000 | $18,870,000,000 |
| Operating Revenue | $21,840,000,000 | $20,178,000,000 | $19,372,000,000 | $18,870,000,000 |
| Expenses | ||||
| Interest Expense | $613,000,000 | $528,000,000 | $452,000,000 | $398,000,000 |
| Total Expenses | $18,854,000,000 | $17,322,000,000 | $16,948,000,000 | $16,395,000,000 |
| Other Income Expense | $-531,000,000 | $-486,000,000 | $-359,000,000 | $-308,000,000 |
| Other Non Operating Income Expenses | $-71,000,000 | $14,000,000 | $-7,000,000 | $-29,000,000 |
| Net Non Operating Interest Income Expense | $-575,000,000 | $-365,000,000 | $-403,000,000 | $-382,000,000 |
| Interest Expense Non Operating | $613,000,000 | $528,000,000 | $452,000,000 | $398,000,000 |
| Operating Expense | $6,939,000,000 | $6,269,000,000 | $5,746,000,000 | $6,002,000,000 |
| Other Operating Expenses | $396,000,000 | $222,000,000 | $-210,000,000 | $37,000,000 |
| Selling And Marketing Expense | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,678,000,000 | $1,705,000,000 | $1,530,000,000 | $1,635,000,000 |
| Net Interest Income | $-575,000,000 | $-365,000,000 | $-403,000,000 | $-382,000,000 |
| Interest Income | $38,000,000 | $163,000,000 | $49,000,000 | $16,000,000 |
| Normalized Income | $2,088,320,000 | $2,130,000,000 | $1,854,192,000 | $1,890,843,000 |
| Net Income From Continuing And Discontinued Operation | $1,678,000,000 | $1,705,000,000 | $1,484,000,000 | $1,779,000,000 |
| Total Operating Income As Reported | $2,579,000,000 | $2,397,000,000 | $2,111,000,000 | $2,282,000,000 |
| Net Income Common Stockholders | $1,678,000,000 | $1,705,000,000 | $1,424,000,000 | $1,689,000,000 |
| Net Income | $1,678,000,000 | $1,705,000,000 | $1,484,000,000 | $1,779,000,000 |
| Net Income Including Noncontrolling Interests | $1,678,000,000 | $1,705,000,000 | $1,484,000,000 | $1,779,000,000 |
| Net Income Discontinuous Operations | $0 | $0 | $-46,000,000 | $144,000,000 |
| Net Income Continuous Operations | $1,678,000,000 | $1,705,000,000 | $1,530,000,000 | $1,635,000,000 |
| Pretax Income | $1,881,000,000 | $2,005,000,000 | $1,662,000,000 | $1,783,000,000 |
| Special Income Charges | $-408,000,000 | $-458,000,000 | $-313,000,000 | $-216,000,000 |
| Interest Income Non Operating | $38,000,000 | $163,000,000 | $49,000,000 | $16,000,000 |
| Operating Income | $2,986,000,000 | $2,856,000,000 | $2,424,000,000 | $2,475,000,000 |
| Gross Profit | $9,925,000,000 | $9,125,000,000 | $8,170,000,000 | $8,477,000,000 |
| Per Share | ||||
| Diluted EPS | $5.82 | $5.93 | $4.94 | $5.88 |
| Basic EPS | $5.83 | $5.96 | $4.97 | $5.93 |
| Other | ||||
| Tax Effect Of Unusual Items | $-49,680,000 | $-75,000,000 | $-27,808,000 | $-23,157,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $5,416,000,000 | $5,319,000,000 | $4,754,000,000 | $4,689,000,000 |
| Total Unusual Items | $-460,000,000 | $-500,000,000 | $-352,000,000 | $-279,000,000 |
| Total Unusual Items Excluding Goodwill | $-460,000,000 | $-500,000,000 | $-352,000,000 | $-279,000,000 |
| Reconciled Depreciation | $2,462,000,000 | $2,286,000,000 | $2,288,000,000 | $2,229,000,000 |
| EBITDA (Bullshit earnings) | $4,956,000,000 | $4,819,000,000 | $4,402,000,000 | $4,410,000,000 |
| EBIT | $2,494,000,000 | $2,533,000,000 | $2,114,000,000 | $2,181,000,000 |
| Diluted Average Shares | $288,509,000 | $291,009,000 | $288,392,000 | $287,364,000 |
| Basic Average Shares | $287,648,000 | $289,763,000 | $286,282,000 | $285,005,000 |
| Diluted NI Availto Com Stockholders | $1,678,000,000 | $1,705,000,000 | $1,424,000,000 | $1,689,000,000 |
| Tax Provision | $203,000,000 | $300,000,000 | $132,000,000 | $148,000,000 |
| Restructuring And Mergern Acquisition | $408,000,000 | $458,000,000 | $313,000,000 | $192,000,000 |
| Gain On Sale Of Security | $-52,000,000 | $-42,000,000 | $-39,000,000 | $-63,000,000 |
| Research And Development | $1,265,000,000 | $1,190,000,000 | $1,237,000,000 | $1,256,000,000 |
| Selling General And Administration | $5,278,000,000 | $4,857,000,000 | $4,719,000,000 | $4,709,000,000 |
| Preferred Stock Dividends | - | - | $60,000,000 | $90,000,000 |
| Other Special Charges | - | - | - | $24,000,000 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-10,626,000,000 | $-11,493,000,000 | $-9,672,000,000 | $-11,648,000,000 |
| Total Assets | $55,325,000,000 | $57,286,000,000 | $52,780,000,000 | $52,934,000,000 |
| Total Non Current Assets | $46,069,000,000 | $46,818,000,000 | $44,104,000,000 | $44,790,000,000 |
| Other Non Current Assets | $3,056,000,000 | $2,615,000,000 | $2,078,000,000 | $1,848,000,000 |
| Goodwill And Other Intangible Assets | $36,016,000,000 | $37,382,000,000 | $35,469,000,000 | $36,930,000,000 |
| Other Intangible Assets | $9,404,000,000 | $10,917,000,000 | $10,947,000,000 | $12,309,000,000 |
| Current Assets | $9,255,000,000 | $10,468,000,000 | $8,676,000,000 | $8,141,000,000 |
| Other Current Assets | $1,508,000,000 | $1,291,000,000 | $1,380,000,000 | $1,559,000,000 |
| Restricted Cash | $210,000,000 | $139,000,000 | $65,000,000 | $153,000,000 |
| Inventory | $3,894,000,000 | $3,843,000,000 | $3,273,000,000 | $3,224,000,000 |
| Receivables | $2,994,000,000 | $3,033,000,000 | $2,534,000,000 | $2,191,000,000 |
| Accounts Receivable | $2,994,000,000 | $3,033,000,000 | $2,534,000,000 | $2,191,000,000 |
| Allowance For Doubtful Accounts Receivable | $-94,000,000 | $-79,000,000 | $-81,000,000 | - |
| Gross Accounts Receivable | $3,088,000,000 | $3,112,000,000 | $2,615,000,000 | - |
| Cash Cash Equivalents And Short Term Investments | $649,000,000 | $2,162,000,000 | $1,424,000,000 | $1,014,000,000 |
| Cash And Cash Equivalents | $641,000,000 | $1,717,000,000 | $1,416,000,000 | $1,006,000,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | $1,559,000,000 |
| Debt | ||||
| Net Debt | $18,540,000,000 | $18,393,000,000 | $14,463,000,000 | $15,059,000,000 |
| Total Debt | $19,181,000,000 | $20,110,000,000 | $15,879,000,000 | $16,065,000,000 |
| Long Term Debt And Capital Lease Obligation | $17,621,000,000 | $17,940,000,000 | $14,738,000,000 | $13,886,000,000 |
| Long Term Debt | $17,621,000,000 | $17,940,000,000 | $14,738,000,000 | $13,886,000,000 |
| Current Debt And Capital Lease Obligation | $1,560,000,000 | $2,170,000,000 | $1,141,000,000 | $2,179,000,000 |
| Current Debt | $1,560,000,000 | $2,170,000,000 | $1,141,000,000 | $2,179,000,000 |
| Other Current Borrowings | $705,000,000 | $1,770,000,000 | $1,141,000,000 | $1,949,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,935,000,000 | $31,397,000,000 | $26,983,000,000 | $27,652,000,000 |
| Total Non Current Liabilities Net Minority Interest | $21,622,000,000 | $22,441,000,000 | $20,342,000,000 | $19,841,000,000 |
| Other Non Current Liabilities | $2,932,000,000 | $3,559,000,000 | $4,581,000,000 | $5,053,000,000 |
| Current Liabilities | $8,313,000,000 | $8,956,000,000 | $6,641,000,000 | $7,811,000,000 |
| Other Current Liabilities | $1,000,000 | - | $1,000,000 | - |
| Payables And Accrued Expenses | $6,752,000,000 | $6,786,000,000 | $5,499,000,000 | $5,632,000,000 |
| Payables | $2,303,000,000 | $2,064,000,000 | $1,780,000,000 | $1,856,000,000 |
| Total Tax Payable | $329,000,000 | $168,000,000 | $139,000,000 | $157,000,000 |
| Income Tax Payable | $329,000,000 | $168,000,000 | $139,000,000 | $157,000,000 |
| Accounts Payable | $1,974,000,000 | $1,896,000,000 | $1,641,000,000 | $1,699,000,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | $5,052,000,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $5,052,000,000 |
| Equity | ||||
| Common Stock Equity | $25,390,000,000 | $25,889,000,000 | $25,797,000,000 | $25,280,000,000 |
| Total Equity Gross Minority Interest | $25,390,000,000 | $25,889,000,000 | $25,797,000,000 | $25,282,000,000 |
| Stockholders Equity | $25,390,000,000 | $25,889,000,000 | $25,797,000,000 | $25,282,000,000 |
| Other Equity Interest | $25,000,000 | $25,000,000 | $24,000,000 | $23,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,895,000,000 | $-1,732,000,000 | $-1,548,000,000 | $-1,488,000,000 |
| Other Equity Adjustments | $-1,895,000,000 | $-1,732,000,000 | $-1,548,000,000 | $-1,488,000,000 |
| Retained Earnings | $16,622,000,000 | $16,139,000,000 | $15,535,000,000 | $15,157,000,000 |
| Preferred Stock Equity | - | - | - | $2,000,000 |
| Other | ||||
| Treasury Shares Number | $85,192,233 | $81,493,082 | $80,202,608 | $81,283,191 |
| Ordinary Shares Number | $285,402,168 | $289,101,319 | $290,391,793 | $283,356,710 |
| Share Issued | $370,594,401 | $370,594,401 | $370,594,401 | $364,639,901 |
| Tangible Book Value | $-10,626,000,000 | $-11,493,000,000 | $-9,672,000,000 | $-11,650,000,000 |
| Invested Capital | $44,571,000,000 | $45,999,000,000 | $41,676,000,000 | $41,345,000,000 |
| Working Capital | $942,000,000 | $1,512,000,000 | $2,035,000,000 | $330,000,000 |
| Total Capitalization | $43,011,000,000 | $43,829,000,000 | $40,535,000,000 | $39,168,000,000 |
| Treasury Stock | $9,808,000,000 | $8,807,000,000 | $8,305,000,000 | $8,330,000,000 |
| Additional Paid In Capital | $20,075,000,000 | $19,893,000,000 | $19,720,000,000 | $19,553,000,000 |
| Capital Stock | $371,000,000 | $371,000,000 | $371,000,000 | $367,000,000 |
| Common Stock | $371,000,000 | $371,000,000 | $371,000,000 | $365,000,000 |
| Employee Benefits | $1,069,000,000 | $942,000,000 | $1,023,000,000 | $902,000,000 |
| Commercial Paper | $855,000,000 | $400,000,000 | $0 | $230,000,000 |
| Current Accrued Expenses | $4,449,000,000 | $4,722,000,000 | $3,719,000,000 | $3,776,000,000 |
| Goodwill | $26,612,000,000 | $26,465,000,000 | $24,522,000,000 | $24,621,000,000 |
| Net PPE | $6,997,000,000 | $6,821,000,000 | $6,557,000,000 | $6,012,000,000 |
| Accumulated Depreciation | $-8,116,000,000 | $-7,557,000,000 | $-7,021,000,000 | $-6,402,000,000 |
| Gross PPE | $15,113,000,000 | $14,378,000,000 | $13,578,000,000 | $12,414,000,000 |
| Leases | $331,000,000 | $320,000,000 | $301,000,000 | $266,000,000 |
| Machinery Furniture Equipment | $10,759,000,000 | $10,197,000,000 | $9,609,000,000 | $8,769,000,000 |
| Buildings And Improvements | $3,895,000,000 | $3,733,000,000 | $3,537,000,000 | $3,252,000,000 |
| Land And Improvements | $128,000,000 | $129,000,000 | $131,000,000 | $127,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,544,000,000 | $2,597,000,000 | $2,178,000,000 | $2,120,000,000 |
| Work In Process | $490,000,000 | $443,000,000 | $381,000,000 | $397,000,000 |
| Raw Materials | $860,000,000 | $803,000,000 | $714,000,000 | $707,000,000 |
| Other Short Term Investments | $8,000,000 | $445,000,000 | $8,000,000 | $8,000,000 |
| Other Properties | - | $-1,000,000 | - | $1,000,000 |
| Preferred Stock | - | - | $0 | $2,000,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $2,671,000,000 | $3,072,000,000 | $2,115,000,000 | $1,660,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $3,431,000,000 | $3,797,000,000 | $2,989,000,000 | $2,633,000,000 |
| Cash From Discontinued Operating Activities | $0 | $-46,000,000 | $-1,000,000 | $163,000,000 |
| Cash Flow From Continuing Operating Activities | $3,431,000,000 | $3,843,000,000 | $2,990,000,000 | $2,470,000,000 |
| Operating Gains Losses | $23,000,000 | $-70,000,000 | $-156,000,000 | $-55,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-760,000,000 | $-725,000,000 | $-874,000,000 | $-973,000,000 |
| Investing Cash Flow | $-818,000,000 | $-5,514,000,000 | $-716,000,000 | $-3,231,000,000 |
| Cash Flow From Continuing Investing Activities | $-818,000,000 | $-5,514,000,000 | $-716,000,000 | $-3,220,000,000 |
| Net Other Investing Changes | $-480,000,000 | $-444,000,000 | $-382,000,000 | $-177,000,000 |
| Capital Expenditure Reported | $-760,000,000 | $-725,000,000 | $-874,000,000 | $-973,000,000 |
| Cash From Discontinued Investing Activities | - | $0 | $0 | $-11,000,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-3,617,000,000 | $2,086,000,000 | $-1,957,000,000 | $-591,000,000 |
| Cash Flow From Continuing Financing Activities | $-3,617,000,000 | $2,086,000,000 | $-1,957,000,000 | $-736,000,000 |
| Net Other Financing Charges | $-87,000,000 | $-89,000,000 | $-120,000,000 | $924,000,000 |
| Cash Dividends Paid | $-1,196,000,000 | $-1,100,000,000 | $-1,114,000,000 | $-1,082,000,000 |
| Common Stock Dividend Paid | $-1,196,000,000 | $-1,100,000,000 | $-1,114,000,000 | $-1,082,000,000 |
| Net Common Stock Issuance | $-1,000,000,000 | $-500,000,000 | $0 | $-500,000,000 |
| Cash From Discontinued Financing Activities | - | $0 | $0 | $145,000,000 |
| Repurchase Of Capital Stock | - | - | - | $-500,000,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-1,789,000,000 | $-1,142,000,000 | $-2,155,000,000 | $-805,000,000 |
| Issuance Of Debt | $0 | $4,517,000,000 | $1,662,000,000 | $497,000,000 |
| End Cash Position | $851,000,000 | $1,856,000,000 | $1,481,000,000 | $1,159,000,000 |
| Beginning Cash Position | $1,856,000,000 | $1,481,000,000 | $1,159,000,000 | $2,392,000,000 |
| Effect Of Exchange Rate Changes | $0 | $4,000,000 | $5,000,000 | $-45,000,000 |
| Changes In Cash | $-1,005,000,000 | $371,000,000 | $317,000,000 | $-1,188,000,000 |
| Net Issuance Payments Of Debt | $-1,334,000,000 | $3,775,000,000 | $-723,000,000 | $-78,000,000 |
| Net Short Term Debt Issuance | $455,000,000 | $400,000,000 | $-230,000,000 | $230,000,000 |
| Net Long Term Debt Issuance | $-1,789,000,000 | $3,375,000,000 | $-493,000,000 | $-308,000,000 |
| Long Term Debt Payments | $-1,789,000,000 | $-1,142,000,000 | $-2,155,000,000 | $-805,000,000 |
| Long Term Debt Issuance | $0 | $4,517,000,000 | $1,662,000,000 | $497,000,000 |
| Net Investment Purchase And Sale | $422,000,000 | $-421,000,000 | $0 | $0 |
| Net Business Purchase And Sale | $0 | $-3,924,000,000 | $540,000,000 | $-2,070,000,000 |
| Sale Of Business | $0 | $0 | $540,000,000 | $0 |
| Purchase Of Business | $0 | $-3,924,000,000 | $0 | $-2,070,000,000 |
| Change In Working Capital | $-800,000,000 | $293,000,000 | $-630,000,000 | $-1,508,000,000 |
| Change In Payables And Accrued Expense | $-185,000,000 | $625,000,000 | $-517,000,000 | $-473,000,000 |
| Change In Payable | $-185,000,000 | $625,000,000 | $-517,000,000 | $-473,000,000 |
| Change In Account Payable | $-185,000,000 | $625,000,000 | $-517,000,000 | $-473,000,000 |
| Change In Prepaid Assets | $-276,000,000 | $23,000,000 | $192,000,000 | $-436,000,000 |
| Change In Inventory | $-410,000,000 | $98,000,000 | $-15,000,000 | $-631,000,000 |
| Change In Receivables | $71,000,000 | $-453,000,000 | $-290,000,000 | $32,000,000 |
| Changes In Account Receivables | $71,000,000 | $-453,000,000 | $-290,000,000 | $32,000,000 |
| Other Non Cash Items | $284,000,000 | $-407,000,000 | $321,000,000 | $56,000,000 |
| Stock Based Compensation | $258,000,000 | $247,000,000 | $259,000,000 | $233,000,000 |
| Deferred Tax | $-474,000,000 | $-211,000,000 | $-622,000,000 | $-120,000,000 |
| Deferred Income Tax | $-474,000,000 | $-211,000,000 | $-622,000,000 | $-120,000,000 |
| Depreciation Amortization Depletion | $2,462,000,000 | $2,286,000,000 | $2,288,000,000 | $2,229,000,000 |
| Depreciation And Amortization | $2,462,000,000 | $2,286,000,000 | $2,288,000,000 | $2,229,000,000 |
| Pension And Employee Benefit Expense | $23,000,000 | $-70,000,000 | $112,000,000 | $-55,000,000 |
| Gain Loss On Sale Of Business | $0 | $0 | $-268,000,000 | $0 |
| Net Income From Continuing Operations | $1,678,000,000 | $1,705,000,000 | $1,530,000,000 | $1,635,000,000 |
| Purchase Of Investment | - | $-421,000,000 | $0 | $0 |
| Excess Tax Benefit From Stock Based Compensation | - | - | $19,000,000 | $32,000,000 |
| Common Stock Payments | - | - | - | $-500,000,000 |
Fetched: 2026-06-17